Q-omics provides the consensus-scored KIF4CP profile across patient tissues and cancer cell-line models. KIF4CP expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIF4CP is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, KIF4CP RNA expression shows 10,520 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BRCA, and LSCC as cancer lineages where KIF4CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF4CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF4CP survival associations across molecular data types. KIF4CP RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF4CP RNA expression–survival associations across cancer types. High KIF4CP expression shows unfavorable associations in KIRC, ACC, CHOL, OV, PAAD and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIF4CP RNA expression.
This table summarizes KIF4CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KIF4CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF4CP shows lower tumor expression in BRCA and THCA and higher tumor expression in STAD. The BRCA box plot shows higher KIF4CP RNA expression in normal versus tumor tissue (log2 FC = −0.026, t-test p = .013).
This table shows molecular features associated with KIF4CP in patient tissues and cancer cell lines. In patient samples, KIF4CP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
